J. Scott Wolchko - 25 Jan 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
25 Jan 2022
Net transactions value
$0
Form type
4
Filing time
27 Jan 2022, 15:09:49 UTC
Previous filing
04 Feb 2022
Next filing
25 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +289,403 $0.000000 289,403 25 Jan 2022 Common Stock 289,403 $39.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.